• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳米混悬液作为某些糖皮质激素药物的眼部给药系统。

Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.

作者信息

Kassem M A, Abdel Rahman A A, Ghorab M M, Ahmed M B, Khalil R M

机构信息

Department of Pharmaceutical Technology, National Research Center, Dokki, Cairo, Egypt.

出版信息

Int J Pharm. 2007 Aug 1;340(1-2):126-33. doi: 10.1016/j.ijpharm.2007.03.011. Epub 2007 Mar 12.

DOI:10.1016/j.ijpharm.2007.03.011
PMID:17600645
Abstract

Poorly-water-soluble compounds are difficult to develop as drug products using conventional formulation techniques. The use of nanotechnology to formulate poorly-water-soluble drugs as nanosuspensions offers the opportunity to address many of the deficiencies associated with this class of molecules. In the present study, the high pressure homogenization method used to prepare nanosuspensions of three practically insoluble glucocorticoid drugs; hydrocortisone, prednisolone and dexamethasone. The effect of particle size in the micron and nano-size ranges as well as the effect of viscosity of the nanosuspension on the ocular bioavailability was studied by measuring the intraocular pressure of normotensive Albino rabbits using shiØetz tonometer. The results show that compared to solution and micro-crystalline suspensions it is a common feature of the three drugs that the nanosuspensions always enhance the rate and extent of ophthalmic drug absorption as well as the intensity of drug action. In the majority of cases nanosuspensions extend the duration of drug effect to a significant extent. The data presented confirms that nanosuspensions differ from micro-crystalline suspensions and solution as ophthalmic drug delivery systems and that the differences are statistically, highly to very highly significant. The results confirm also the importance of viscosity of nanosuspension especially in increasing the duration of drug action.

摘要

使用传统制剂技术将水溶性差的化合物开发成药品很困难。利用纳米技术将水溶性差的药物制成纳米混悬液,为解决与这类分子相关的许多缺陷提供了契机。在本研究中,采用高压均质法制备了三种几乎不溶性糖皮质激素药物(氢化可的松、泼尼松龙和地塞米松)的纳米混悬液。通过使用施-茨眼压计测量正常血压白化兔的眼压,研究了微米和纳米尺寸范围内的粒径以及纳米混悬液的粘度对眼部生物利用度的影响。结果表明,与溶液和微晶混悬液相比,这三种药物的共同特点是纳米混悬液总能提高眼科药物的吸收速率和程度以及药物作用强度。在大多数情况下,纳米混悬液能显著延长药物作用持续时间。所呈现的数据证实,作为眼科药物递送系统,纳米混悬液与微晶混悬液和溶液不同,且这些差异在统计学上具有高度到非常高度的显著性。结果还证实了纳米混悬液粘度的重要性,尤其是在延长药物作用持续时间方面。

相似文献

1
Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.纳米混悬液作为某些糖皮质激素药物的眼部给药系统。
Int J Pharm. 2007 Aug 1;340(1-2):126-33. doi: 10.1016/j.ijpharm.2007.03.011. Epub 2007 Mar 12.
2
Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling.水凝胶纳米混悬剂用于眼部给药:微流控纳米沉淀法和湿法研磨法的比较研究。
J Control Release. 2011 Jan 20;149(2):175-81. doi: 10.1016/j.jconrel.2010.10.007. Epub 2010 Oct 11.
3
Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability.自组装液晶纳米粒作为一种新型的地塞米松眼部给药系统:提高了眼表滞留和眼部生物利用度。
Int J Pharm. 2010 Aug 30;396(1-2):179-87. doi: 10.1016/j.ijpharm.2010.06.015. Epub 2010 Jun 15.
4
Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops.用于眼部后段给药的环糊精微粒:地塞米松水性滴眼液
J Pharm Pharmacol. 2007 May;59(5):629-35. doi: 10.1211/jpp.59.5.0002.
5
Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.用于提高难溶性药物溶出度的纳米混悬液的制备与评价
Int J Pharm. 2006 Apr 7;312(1-2):179-86. doi: 10.1016/j.ijpharm.2006.01.008. Epub 2006 Feb 15.
6
Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS).基于固化反胶束溶液(SRMS)的纳米混悬液的药物释放与渗透研究。
Int J Pharm. 2005 Nov 23;305(1-2):167-75. doi: 10.1016/j.ijpharm.2005.09.007. Epub 2005 Oct 19.
7
Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.冬凌草甲素纳米混悬液的药代动力学及组织分布研究
Int J Pharm. 2008 May 1;355(1-2):321-7. doi: 10.1016/j.ijpharm.2007.12.016. Epub 2007 Dec 23.
8
A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound.使用一种难溶性化合物的溶液和不同纳米混悬液进行制剂比较。
Eur J Pharm Biopharm. 2007 Sep;67(2):540-7. doi: 10.1016/j.ejpb.2007.02.008. Epub 2007 Feb 17.
9
Preparation of a chemically stable quercetin formulation using nanosuspension technology.采用纳米混悬技术制备化学稳定性良好的槲皮素制剂。
Int J Pharm. 2011 Feb 14;404(1-2):231-7. doi: 10.1016/j.ijpharm.2010.11.009. Epub 2010 Nov 17.
10
Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.与微粉化药物的传统混悬剂相比,口服非诺贝特纳米混悬剂和固体脂质纳米粒的药代动力学评价
Adv Drug Deliv Rev. 2007 Jul 10;59(6):419-26. doi: 10.1016/j.addr.2007.04.005. Epub 2007 May 3.

引用本文的文献

1
Nanovesicular Drug Delivery Systems for Rare Ocular Diseases: Advances, Challenges, and Future Directions.用于罕见眼科疾病的纳米囊泡给药系统:进展、挑战与未来方向
AAPS PharmSciTech. 2025 Jul 23;26(7):197. doi: 10.1208/s12249-025-03159-8.
2
Formulation and Development of Nanofiber-Based Ophthalmic Insert for the Treatment of Bacterial Conjunctivitis.基于纳米纤维的眼科植入物的配方与开发,用于治疗细菌性结膜炎。
Int J Mol Sci. 2024 Aug 25;25(17):9228. doi: 10.3390/ijms25179228.
3
Nanosuspension-Based Drug Delivery Systems for Topical Applications.
基于纳米混悬剂的经皮给药系统。
Int J Nanomedicine. 2024 Jan 25;19:825-844. doi: 10.2147/IJN.S447429. eCollection 2024.
4
Overview of processed excipients in ocular drug delivery: Opportunities so far and bottlenecks.眼部药物递送中辅料加工概述:迄今的机遇与瓶颈
Heliyon. 2023 Dec 23;10(1):e23810. doi: 10.1016/j.heliyon.2023.e23810. eCollection 2024 Jan 15.
5
Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.基于可生物降解聚合物的眼部疾病药物传递系统。
Int J Mol Sci. 2023 Aug 19;24(16):12976. doi: 10.3390/ijms241612976.
6
Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases.眼部给药系统的最新进展:眼用植入物在慢性眼病治疗中的突出地位。
Pharmaceutics. 2023 Jun 15;15(6):1746. doi: 10.3390/pharmaceutics15061746.
7
Formulation Strategies of Nanosuspensions for Various Administration Routes.用于不同给药途径的纳米混悬液的制剂策略
Pharmaceutics. 2023 May 17;15(5):1520. doi: 10.3390/pharmaceutics15051520.
8
Updates on Biodegradable Formulations for Ocular Drug Delivery.眼部给药用可生物降解制剂的研究进展
Pharmaceutics. 2023 Feb 22;15(3):734. doi: 10.3390/pharmaceutics15030734.
9
Topical Application of Linezolid-Loaded Chitosan Nanoparticles for the Treatment of Eye Infections.负载利奈唑胺的壳聚糖纳米颗粒局部应用于眼部感染治疗
Nanomaterials (Basel). 2023 Feb 9;13(4):681. doi: 10.3390/nano13040681.
10
Nanocrystallization Improves the Solubilization and Cytotoxic Effect of a Poly (ADP-Ribose)-Polymerase-I Inhibitor.纳米晶化改善聚(ADP - 核糖)聚合酶 - I抑制剂的溶解性和细胞毒性作用。
Polymers (Basel). 2022 Nov 9;14(22):4827. doi: 10.3390/polym14224827.